rs548024862
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_015450.3(POT1):c.1442A>G(p.Glu481Gly) variant causes a missense change. The variant allele was found at a frequency of 0.0000781 in 1,614,016 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_015450.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POT1 | NM_015450.3 | c.1442A>G | p.Glu481Gly | missense_variant | Exon 15 of 19 | ENST00000357628.8 | NP_056265.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152202Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000398 AC: 10AN: 251414Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135880
GnomAD4 exome AF: 0.0000828 AC: 121AN: 1461814Hom.: 0 Cov.: 33 AF XY: 0.0000908 AC XY: 66AN XY: 727206
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152202Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74350
ClinVar
Submissions by phenotype
not provided Uncertain:2
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Observed in a control individual and not in any melanoma cases (Simonin-Wilmer et al., 2022); This variant is associated with the following publications: (PMID: 28393830, 36539277) -
The POT1 c.1442A>G (p.Glu481Gly) variant has been observed in a reportedly healthy individual in a melanoma case-control study (PMID: 36539277 (2022)). The frequency of this variant in the general population, 0.00014 (5/35440 chromosomes in Admixed American subpopulation (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is higher than would generally be expected for pathogenic variants in this gene. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
not specified Uncertain:1
DNA sequence analysis of the POT1 gene demonstrated a sequence change, c.1442A>G, in exon 15 that results in an amino acid change, p.Glu481Gly. This sequence change does not appear to have been previously described in individuals with POT1-related disorders and has been described in the gnomAD database with a frequency of 0.0039%in the overall population (dbSNP rs548024862). The p.Glu481Gly change affects a moderately conserved amino acid residue located in a domain of the POT1 protein that is not known to be functional. The p.Glu481Gly substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Glu481Gly change remains unknown at this time. -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.E481G variant (also known as c.1442A>G), located in coding exon 11 of the POT1 gene, results from an A to G substitution at nucleotide position 1442. The glutamic acid at codon 481 is replaced by glycine, an amino acid with similar properties. This alteration was identified in 0 of 2928 melanoma cases and 1 of 3298 controls (Simonin-Wilmer I et al. J Med Genet, 2023 Jul;60:692-696). Functional studies suggest this alteration does not impact telomere binding; however, additional evidence is needed to confirm this finding (Simonin-Wilmer I et al. J Med Genet, 2023 Jul;60:692-696). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Tumor predisposition syndrome 3 Uncertain:1
This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 481 of the POT1 protein (p.Glu481Gly). This variant is present in population databases (rs548024862, gnomAD 0.01%). This missense change has been observed in individual(s) with thyroid cancer (PMID: 38688277). ClinVar contains an entry for this variant (Variation ID: 574289). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt POT1 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at